Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ulocuplumab + lenalidomide + dexamethasone
- Development stage
- Unknown
- Lead developer
- Bristol Myers Squibb
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous, Oral
01
Overview
**Ulocuplumab + lenalidomide + dexamethasone** is an investigational three-drug combination regimen studied for the treatment of relapsed or refractory multiple myeloma. - **Ulocuplumab** is a fully human monoclonal antibody targeting C-X-C chemokine receptor type 4 (CXCR4), which plays a role in cancer cell migration, adhesion, and tumor microenvironment interaction. - **Lenalidomide** is an immunomodulatory small molecule, analog of thalidomide, with direct anti-neoplastic, anti-angiogenic, and immunomodulatory effects, primarily used in hematologic malignancies such as multiple myeloma[1][3]. - **Dexamethasone** is a synthetic glucocorticoid with immunosuppressive and anti-inflammatory properties and is used as a backbone therapy in multiple myeloma[3]. This specific three-drug combination is being explored to potentially improve outcomes in patients with multiple myeloma, particularly by disrupting the protective tumor microenvironment through CXCR4 inhibition and by enhancing antitumor immunity and apoptosis.
- Other names
- ulocuplumab + lenalidomide + dexamethasone
02
Targets
CRBN (Cereblon)CXCR4 (C-X-C motif chemokine receptor 4)GR (Glucocorticoid receptor)
Beyond the preview
Go deeper on ulocuplumab + lenalidomide + dexamethasone.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ulocuplumab + lenalidomide + dexamethasone.